Abstract:Treatment of healthy donors with recombinant human granulocyte colony-stimulating factor (rhG-CSF) allows the mobilization and peripheralization into circulating blood of an adequate number of CD34+ cells that can then be collected by leukapheresis (PBSC). This procedure avoids the invasiveness of bone marrow harvest and the risks related to general anesthesia. The main adverse effects of rhG-CSF are: bone pain, 84%, headache, 54%, fatigue, 31%, and nausea, 13%, which are usually scored by the donors as moderate to severe, resolving within 2-3 days after discontinuation of the cytokine. Analgesics, mainly acetaminophen, are sufficient to control the pain. Less than 5% of the donors experience non-cardiac chest pain, a local reaction at the injection site, insomnia, dizziness or a low-grade fever. Discontinuation of the PBSC procedure because of adverse effects of rhG-CSF or leukapheresis is rarely necessary (0.5%) but this good tolerability can be hampered by the need, in 5-20% of cases, for an adequate venous access that requires insertion of a central or venous catheter. There are no absolute contraindications to the stimulation of healthy donors with rhG-CSF but the description of cases of non-traumatic splenic rupture, iritis, cardiac ischemia, and gouty arthritis suggests that further precautionary restrictions are advisable when deciding eligibility for PBSC collection. The main advantages for patients receiving an allogeneic PBSC transplant are the faster hematologic and immunologic recovery and the potential for a greater efficacy in advanced disease by lowering the transplant-related mortality. One of the major concerns regarding the use of rhG-CSF in unrelated healthy donors is the uncertainty about its possible role in triggering malignancy, in particular myelodysplastic syndrome and acute myeloid leukemia. There are no studies with an adequate sample size and follow-up that can answer this question but two recent retrospective studies reported that in the medium term rhG-CSF is not associated with an excess of lymphoproliferative disorders. Currently, caution on the long-term safety of the use of rhG-CSF in healthy donor is still warranted but the data so far accumulated on allogeneic PBSC transplants are encouraging both as far as concerns the good short-medium tolerability profile of G-CSF-stimulation of the donor and the potential major efficacy in leukemia patients.

Alloantigen presenting capacity, T cell alloreactivity and NK function of G-CSF-mobilized peripheral blood cells

An Unbalanced Monocyte Macrophage Polarization In The Bone Marrow Microenvironment Of Patients With Poor Graft Function After Allogeneic Hematopoietic Stem Cell Transplantation

Peripheral Blood Stem Cell Mobilization in Healthy Donors by Granulocyte Colony-Stimulating Factor Causes Preferential Mobilization of Lymphocyte Subsets

A Study of Allogeneic Peripheral Blood Stem Cell Mobilization with G-CSF

The use of cytokine-stimulated healthy donors in allogeneic stem cell transplantation.

[Surgical treatment of anterior chest wall deformities by sternochondroplasty and internal fixation without prosthesis].

Modification of NK cell subset repartition and functions in granulocyte colony-stimulating factor-mobilized leukapheresis after expansion with IL-15

Maintaining hyporesponsiveness and polarization potential of T cells after in vitro mixture of G-CSF mobilized peripheral blood grafts and G-CSF primed bone marrow grafts in different proportions.

Restoration of T and NK cell function in GM-CSF mobilized stem cell products from breast cancer patients by monocyte depletion

Effect of the in vivo application of granulocyte colony-stimulating factor on NK cells in bone marrow and peripheral blood.

Immune Tolerance Induced by Cytokines in Allogeneic Hematopoietic Stem Cell Transplantation

Randomized comparison of G-CSF + GM-CSF vs G-CSF alone for mobilization of peripheral blood stem cells: effects on hematopoietic recovery after high-dose chemotherapy

Fibrosis of the appendix.

The genomic landscape of the somatic linker histone subtypes H1.1 to H1.5 in human cells.

[A Comparison of NK Cell Subsets Between Rhg-Csf Mobilized Peripheral Blood Grafts and Bone Marrow Grafts from Healthy Donors].

Effects of granulocyte-colony-stimulating factor and granulocyte/macrophage-colony-stimulating factor administration on T cell proliferation and phagocyte cell-surface molecules during hematopoietic reconstitution after autologous peripheral blood progenitor cell transplantation

[Factors Affecting Mobilization of Peripheral Blood Stem/progenitor Cells and Apheresis Efficiency from Healthy Donors by Rhg-Csf].

[Effects of Rhg-Csf Mobilization on Immunological Properties of Grafts from Peripheral Blood and Bone Marrow].

[Influence of G-CSF Mobilization on Functions of Donor T Lymphocyte Subpopulation and Acute Graft-Versus-host Disease].

Effects of rhG-CSF mobilization on immunological characteristics of peripheral blood grafts and steady-state bone marrow

Association of Natural Killer Cells in Allografts with Transplant Outcomes in Patients Receiving G-Csf-Mobilized Pbsc Grafts and G-Csf-Primed Bm Grafts from Hla-Haploidentical Donors